衞寧健康(300253.SZ):基於WiNGPT的醫護智能助手WiNEX Copilot目前已在試點醫院用户使用
格隆匯9月13日丨衞寧健康(300253.SZ)於2024年9月13日召開業績説明會,就“在人工智能、大數據等新興技術與醫療健康領域的融合方面,公司有哪些具體的應用案例和成果?未來如何進一步加強技術創新,推動業務發展?”,公司表示,比如,衞寧健康基於WiNGPT的醫護智能助手WiNEX Copilot目前已在試點醫院用户使用,具體用户名稱現階段暫不方便公佈。未來公司還將繼續加強技術和產品創新,以引領行業向前發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.